Outcomes and management of Peyronie’s disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil
Asian Journal of Andrology · 2025
DOI: 10.4103/aja202514 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Andrology, 2025. Verfasst von Raidh Talib Alzubaidi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Urology/Andrology, Aisha Bint Hamad Al Attiyah Hospital, Doha 3050, Qatar. Hauptthemen laut MEDLINE: Penile Induration, Tadalafil, Microbial Collagenase, Phosphodiesterase 5 Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Peyronie’s disease (PD) is a connective tissue disorder characterized by abnormal collagen deposition in the tunica albuginea, leading to penile curvature, pain, and erectile dysfunction. This study aimed to evaluate the outcomes of a combined treatment protocol incorporating collagenase clostridium histolyticum (CCH), vacuum erection device, and tadalafil. A retrospective analysis was conducted on 99 male patients with PD treated at the Department of Urology, Hamad Medical Corporation (Doha, Qatar) between January 2018 and January 2020. Patients received 4–8 CCH injections alongside vacuum therapy and daily tadalafil (5 mg). The baseline mean penile curvature of 49.0° improved by an average of 21.4% post-treatment. Erectile function scores also increased significantly, with a mean improvement of 2.3 points on the International Index of Erectile Function. Minor complications were observed in 15 patients, while 13 were dissatisfied with treatment, with six opting for surgery. The modified protocol demonstrated significant improvements in penile curvature and erectile function with minimal complications, offering a safe, cost-effective alternative to traditional intensive treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Urology/Andrology, Aisha Bint Hamad Al Attiyah Hospital, Doha 3050, Qatar.
- Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha 3050, Qatar.
- Department of Biomedical Sciences, QU-Health, College of Health Sciences, Qatar University, Doha 2713, Qatar.
- Department of Chemistry, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan.
- Dresden International University, Center of Medicine and Health Sciences, Dresden 01069, Germany.
Zitieren
APA
Alzubaidi, R. T., Abdelkareem, M., Al-Zoubi, R. M., Al-Qudimat, A. R., Yasin, A., Kamkoum, H., & Al-Ansari, A. A. (2025). Outcomes and management of Peyronie’s disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil. Asian Journal of Andrology. https://doi.org/10.4103/aja202514
Vancouver
Alzubaidi RT, Abdelkareem M, Al-Zoubi RM, Al-Qudimat AR, Yasin A, Kamkoum H, et al. Outcomes and management of Peyronie’s disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil. Asian Journal of Andrology. 2025. doi:10.4103/aja202514
BibTeX
@article{Alzubaidi2025,
author = {Alzubaidi, Raidh Talib and Abdelkareem, Mohamed and Al-Zoubi, Raed M and Al-Qudimat, Ahmad R and Yasin, Aksam and Kamkoum, Hatem and Al-Ansari, Abdullah A},
title = {Outcomes and management of Peyronie’s disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil},
journal = {Asian Journal of Andrology},
year = {2025},
doi = {10.4103/aja202514}
}
EUVIMED